MP91-11 POSITIVE EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) ON RENAL FUNCTION IN HYPOGONADAL MEN: REAL-LIFE DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I1 Apr 2017MP91-11 POSITIVE EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) ON RENAL FUNCTION IN HYPOGONADAL MEN: REAL-LIFE DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY Aksam Yassin, Dany-Jan Yassin, Gheorge Doros, and Abdulmaged Traish Aksam YassinAksam Yassin More articles by this author , Dany-Jan YassinDany-Jan Yassin More articles by this author , Gheorge DorosGheorge Doros More articles by this author , and Abdulmaged TraishAbdulmaged Traish More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2851AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A registry was established to assess long-term effectiveness and safety of testosterone undecanoate injections (TU) in a urological setting in comparison to an untreated hypogonadal control group. Parameters related to renal function were measured to gain insight on effects of testosterone therapy (TTh) on renal function. METHODS Observational, prospective, cumulative registry study in 505 men (age: 61.4 ± 9.7 years) with total testosterone (T) levels ≤350 ng/dL and symptoms of hypogonadism. 321 men received parenteral TU 1000 mg/12 weeks following an initial 6-week interval for up to 12 years (T-group). 184 men had opted against TTh and served as controls (CTRL). 8-year data were analyzed. Renal profile was assessed by (Creatinine, Urea, Uric acid and Glomerular filtration rate measured according to Mayo Clinic setting) RESULTS Creatinine decreased from 1.14±0.18 to 1.07±0.8 mg/dL in the T-group and increased from 0.99±0.25 to 1.13±0.53 in CTRL. Uric acid decreased from 6.8±1.5 to 5.5±1.6 mg/dL in the T-group (p<0.0001) and from 5.7±1.5 to 5.2±1.5 mg/dL in CTRL (p<0.01). Urea was only available for the T-group and decreased from 47.5±12.0 to 31.7±12.9 mg/dL (p<0.0001). Glomerular filtration rate (GFR) increased from 86.6±12.8 to 98.5±8.6 mL/min/1.73 m2 in the T-group and decreased from 90.8±20.2 to 87.0±26.0 mL/min/1.73 m2 in CTRL (p<0.0001 for both). γ-GT decreased from 39.31±11.62 to 28.95±7.57 U/L in the T-group (p<0.0001) and increased from 37.79±29.55 to 39.5±26.71 U/L in CTRL (p<0.0005). Bilirubin decreased from 1.64±4.13 to 1.21±1.89 mg/dL in the T-group (p<0.05) and increased from 1.04±7.08 to 1.12±1.96 mg/dL in CTRL (NS). AST remained stable in both groups, ALT declined slightly in both groups. Medication adherence in the T-group was 100 per cent as all injections were administered in the office and documented. There were 25 deaths (7.8%) in the T-group of which 11 (44%) were cardiovascular. In CTRL, 28 patients (15.2%) died, and all deaths (100%) were attributed to cardiovascular causes. CONCLUSIONS Long-term TTh with TU in an unselected hypogonadal men resulted in improvement of renal function, whereas there was a slight worsening in untreated controls. Since renal function may be related to cardiovascular risk, the observed changes may have contributed to a reduction in mortality. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1222 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Aksam Yassin More articles by this author Dany-Jan Yassin More articles by this author Gheorge Doros More articles by this author Abdulmaged Traish More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...